An Observational Study of NeoRecormon (Epoetin Beta) in Cancer Patients With Anemia (FAST)
Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
This observational study will evaluate the clinical benefit of NeoRecormon (epoetin beta) in
daily routine practice in cancer patients with anemia. Data will be collected from patients
who are receiving chemotherapy for a solid tumor or hematological malignancy. Patients will
be followed for 28 weeks.